Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation.

Trial Profile

Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 May 2017

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Etoposide; Idarubicin; Pegfilgrastim; Tretinoin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jan 2014 As per the ClinicalTrials.gov record, planned End Date changed from 1 Feb 2016 to 1 Jan 2020.
    • 10 Jul 2012 Planned End Date changed from 1 Feb 2014 to 1 Feb 2016 as reported by ClinicalTrials.gov.
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register: DRKS00003759).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top